The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EUR 40 million. The loan may be used to further support the clinical development of melflufen and the company’s transition from a R&D company into a fully integrated global biopharmaceutical company. In connection with the loan agreement, Oncopeptides has entered into a warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen. The company’s shares are admitted to trading on Nasdaq Stockholm.
Vinge’s team has consisted of Louise Brorsson Salomon, Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Viktor Lennartsson.
